

Figure S1 Comparison of survival curve between liver metastasis and without liver metastasis groups. (A) The progression-free survival curve of liver metastasis and without liver metastasis groups. (B) The overall survival curve of liver metastasis and without liver metastasis groups.



Figure S2 Comparison of survival curve between $EGFR^{T790M}$-positive and $EGFR^{T790M}$-negative groups. (A) The progression-free survival curve of $EGFR^{T790M}$-positive and $EGFR^{T790M}$-negative groups. (B) The overall survival curve of $EGFR^{T790M}$-positive and $EGFR^{T790M}$-negative groups.

https://dx.doi.org/10.21037/atm-22-6272

Table S1 Median PFS and OS in different treatment subgroups

Variable	mPFS (months, 95% CI)	P value	mOS (months, 95% CI)	P value
ICI treatment regimen		0.946		0.837
IM	3.93 (1.56–6.31)		5.97 (3.57–15.26)	
I+A	4.70 (2.98–6.42)		9.03 (6.55–11-51)	
I+C	5.00 (2.44–7.56)		11.33 (6.81–15.85)	
I+A+C	6.10 (3.857–8.343)		11.50 (9.17–13.83)	

PFS, progression-free survival; OS, overall survival; I, immune checkpoint inhibitors; IM, immune monotherapy; A, antiangiogenic drug; C, chemotherapy; ICI: immune checkpoint inhibitors; CI: confidence interval.

Table S2 Tumor response of patients for 2 EGFR-mutated types

Variable	Exon 19 del (N = 39)	Exon 21 L858R (N = 51)	P value
Best overall response—N (%)			
Complete response	0 (0)	0 (0)	
Partial response	5 (12.8%)	14 (27.5%)	
Stable disease	21 (53.8%)	29 (56.8%)	
Progressive disease	13 (33.3%)	8 (15.7%)	
Disease control rate	66.7%	84.3%	0.049*
Time to response—M[†]			
Median	1.4	1.4	0.950
Range	—	1.3–1.5	
Duration of response—M[†]			
Median	6.9	7.1	0.952
Range	6.0–7.7	6.4–7.7	

EGFR = epidermal growth factor receptor, N = number, M = month, disease control rate = the patients who had complete response or partial response, time to response = the time from immunotherapy beginning to the date of first documented complete or partial response, duration of response = the time between the date of first response and the date of first documented event of progression or death. [†]Results were calculated with the use of the Kaplan–Meier method. *represents a statistically significant difference.

https://dx.doi.org/10.21037/atm-22-6272

Table S3 Adverse events in different groups

Adverse events	Treatment-related adverse events		Immune-related adverse events	
	All grades	Grade 3–5	All grades	Grade 3–5
Driver mutation				
Exon 19 del	82.1%	17.9%	33.3%	10.3%
Exon 21 L858R	72.5%	17.6%	33.3%	5.9%
T790M mutation				
Positive	79.5%	17.9%	28.2%	2.6%
Negative	73.3%	16.7%	30.0%	10.0%
Age				
<60	73.6%	15.3%	29.2%	5.6%
≥60	83.3%	23.3%	36.7%	10.0%
ICI treatment regimen				
IM	50.0%	0.0%	10.0%	0.0%
I+A	72.7%	13.6%	50.0%	13.6%
I+C	81.6%	26.5%	30.6%	8.2%
I+A+C	81.0%	14.3%	23.8%	0.0%

ICI: immune checkpoint inhibitors; I, immune checkpoint inhibitors; IM, immune monotherapy; A, antiangiogenic drug; C, chemotherapy.

https://dx.doi.org/10.21037/atm-22-6272